Insider buying
~$18K10K sh @ $1.79
9 days before resultsTraded Nov 3 · filed 3 days later
A major shareholder of Grace Therapeutics paid $18K out of pocket for Grace Therapeutics shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 4, 2026 · Filed Nov 6, 2026
A major shareholder of Grace Therapeutics paid $9.1K out of pocket for Grace Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$9,060
Shares × reported transaction price
<$25K
+0.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 21 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
83 days after results of Aug 13, 2026, 8 days before results of Nov 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1.81 on Nov 4, 2026, at its 52-week low, after a 15% drop over the previous 30 trading days
52-week range $1.81 (Oct 26, 2026) to $5.13 (Apr 2, 2026), 0% of the way up, from 251 adjusted closes. 30 trading days earlier: $2.12 on Sep 23, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 8 days before GRCE reported its results (Nov 12, 2026)
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.2% | +2.6% | −4.8% |
Past results only. Not a forecast.
Insider buying
9 days before resultsTraded Nov 3 · filed 3 days later
A major shareholder of Grace Therapeutics paid $18K out of pocket for Grace Therapeutics shares.
Insider buying
7 days before resultsTraded Nov 5 · filed 1 day later
A major shareholder of Grace Therapeutics paid $5.5K out of pocket for Grace Therapeutics shares.
Insider buying
Traded Oct 22 · filed 4 days later
A major shareholder of Grace Therapeutics paid $41K out of pocket for Grace Therapeutics shares.
Opaleye Management Inc., 10% owner's past purchases, 90 days after disclosure: 64 buys, median +3.2 pts vs S&P 500, beat it 36 of 64 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.